USPTO serial 85082509
IMMIPRINT
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- WATSON, JULIE A
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with IMMIPRINT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Howard N. Aronson
HOWARD N. ARONSON LACKENBACH SIEGEL LLP1 CHASE RDSCARSDALE, NY 10583-4156UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biochemical assays and reagents for use in science, industrial research and medical research | ABANDONED | — |
| 005 | Medical and veterinary diagnostic test set-ups composed primarily of chemical and/or biochemical reagents used in diagnosing human and animal diseases; diagnostic preparations for medical and veterinary purposes; chemical reagents for medical or veterinary purposes; reagents for medical or veterinary diagnostic purposes | ABANDONED | — |
| 010 | Apparatus for clinical, medical and veterinary diagnosis, namely, microplate readers for blood and body fluid based diagnostic testing, antibody bio-chips for blood and body fluid based diagnostic testing, flow cytometers for blood and body fluid based diagnostic testing, immuno detectors for blood and body fluid based diagnostic testing, microfluidic biochips for blood and body fluid based diagnostic testing, photometers for blood and body fluid based diagnostic testing, piezo electrical transducers for blood and body fluid based diagnostic testing, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing: medical and veterinary testing apparatus for diagnosing human and animal diseases, in particular ones containing chemical and/or biochemical reagents, namely, microplate readers for blood and body fluid based diagnostic testing, antibody bio-chips for blood and body fluid based diagnostic testing, flow cytometers for blood and body fluid based diagnostic testing, immuno detectors for blood and body fluid based diagnostic testing, microfluidic bio-chips for blood and body fluid based diagnostic testing, photometers for blood and body fluid based diagnostic testing, piezo electrical transducers for blood and body fluid based diagnostic testing, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing; laboratory apparatus and equipment for use in the detection of soluble CD antigens, soluble immune system proteins and other soluble proteins in bodily fluids all for diagnosis and monitoring of human and animal diseases and for the monitoring of treatments and therapies for human and animal diseases, namely, microplate readers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, antibody biochips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, flow cytometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, immuno detectors for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, microfluidic bio-chips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, photometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, piezo electrical transducers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification; scientific apparatus and equipment for use in the detection of soluble CD antigens, soluble immune system proteins and other soluble proteins in bodily fluids all for use in the diagnosis and monitoring of human and animal diseases and for the monitoring of treatments and therapies for human and animal diseases, namely, microplate readers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, antibody bio-chips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, flow cytometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, immuno detectors for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, microfluidic bio-chips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, photometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, piezo electrical transducers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification | ABANDONED | — |
| 044 | Medical analyses, namely, RNA or DNA analyses for diagnosing human and animal diseases and forecasting the expected progress of human and animal diseases, all provided during the course of medical treatment or diagnosis and not for medical research purposes | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ProteinLogic Limited
- Other trademarks owned by ProteinLogic Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named IMMIPRINT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 14, 2013 | MAB5 | ABANDONMENT NOTICE MAILED - AFTER PUBLICATION | — |
| Nov 14, 2013 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Nov 13, 2013 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| May 16, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2013 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 10, 2013 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 10, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 14, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 13, 2012 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 9, 2012 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 9, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 22, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 18, 2012 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 18, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 26, 2012 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 26, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 15, 2011 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 20, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 20, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 17, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 8, 2011 | ALIE | ASSIGNED TO LIE | — |
| Jul 26, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 26, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 26, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 26, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 26, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 7, 2011 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 7, 2011 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 7, 2011 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 18, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 17, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 17, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 25, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 15, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 15, 2010 | NWAP | NEW APPLICATION ENTERED | — |